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Many clinical trials have been carried out or are in progress to assess the therapeutic potential of dendritic-cell- (DC-) based
vaccines on cancer patients, and recently the ﬁrst DC-based vaccine for human cancer was approved by the FDA. Herewith, we
describe the general characteristics of DCs and diﬀerent strategies to generate eﬀective antitumor DC vaccines. In recent years,
the relevance of the tumor microenvironment in the progression of cancer has been highlighted. It has been shown that the
tumormicroenvironmentiscapableofinactivatingvariouscomponentsoftheimmunesystemresponsiblefortumorclearance. In
particular, the eﬀect of the tumor microenvironment on antigen-presenting cells, such as DCs, does not only render these immune
cells unable to induce speciﬁc immune responses, but also turns them into promoters of tumor growth. We also describe strategies
likely to increase the eﬃcacy of DC vaccines by reprogramming the immunosuppressive nature of the tumor microenvironment.
1. GeneralCharacteristics of Dendritic Cells
Dendritic cells (DCs) are professional antigen-presenting
cells (APCs) found in peripheral tissues and in immuno-
logical organs such as the thymus, bone marrow, spleen,
lymph nodes, and Peyer’s patches [1–3]. Their function
is to scan peripheral tissues where they recognize, take
up and process pathogens and present pathogen-derived
antigenic peptides in the context of major histocompatibility
molecules (MHCs) to naive T lymphocytes at lymphoid
organs [4, 5]. Through these processes, DCs form a critical
link between innate and adaptive immunity and are essential
for the development of antigen-speciﬁc immune responses.
To understand how DCs function in the development of
adaptive immunity and the role of DCs in disease, one must
ﬁrst understand the distinguishing characteristics of innate
and adaptive immunity.
Innate immunity is the ﬁrst response to an immunologi-
cal challenge, and the onset of an innate immune response
is very rapid. Once a foreign pathogen breeches the outer
barrier of the skin and enters the body, several innate
immune cells are present to resolve this challenge. Some of
the key immune cells that participate in the innate immune
response include macrophages, granulocytes, DCs, and nat-
ural killer (NK) cells. Macrophages, along with granulocytes
a n dD C s ,a r ea l lp h a g o c y t i cc e l l sf o u n di nt i s s u e s .A f t e r
taking up a pathogen, these phagocytic cells are able to
eliminate it through several mechanisms such as reactive
oxygen or nitrogen species. The means by which pathogens
are detected by phagocytes is through the expression of
conserved pathogen-associated molecular patterns (PAMPs)
present on the cell surface of the pathogen. These PAMPs are
detected by pattern recognition receptors (PRRs) expressed
on the cell surface of the phagocyte. Through pathogen
recognition by PRRs, the phagocytes of the innate immune
response are able to distinguish between self and foreign
(non-self) cells. Some of the main PRRs active in innate
immunity include Toll-like receptors (TLRs) and NOD-like
receptors (NLRs) [6, 7].2 Journal of Biomedicine and Biotechnology
2.DCActivationProcess
Immature DCs present in peripheral tissues can detect
foreign PAMP-bearing microorganisms through their high
expression of cell surface and vesicular PRRs [8]. Follow-
ing recognition, DCs take up pathogens by phagocytosis
and process them into peptide fragments [3]. Since not
all pathogens are eliminated by the innate immunity, an
adaptive immune response may be needed to target anti-
genic epitopes associated with the pathogen to resolve the
immunological threat completely. Antigenic peptide frag-
ments derived from the processed pathogen are bound and
presented on the DC surface by MHC molecules. These
MHC molecules can evoke the adaptive immune response by
presenting antigenic peptides to na¨ ıve T cell receptors [3].
An immature DC that has processed a pathogen will
undergo maturation in the presence of proinﬂammatory
cytokines and migrate to lymphoid regions where it can
present the antigen peptide to na¨ ıve T lymphocytes [3, 4].
The maturation process involves upregulation of MHC class
II molecules, costimulatory molecules such as CD40, CD80,
CD86, and OX40L, and the chemokine receptor CCR7, while
downregulating the expression of the chemokine receptor
CCR6. Upon maturation, DCs show a decrease in their
phagocytic capability, an augment in their eﬃcacy to present
processed antigens in the context of MHC molecules, and
consequently an improved capability to activate T cells.
Chemokines CCL19 (ELC) and CCL21 (SLC), ligands for
CCR7, are constitutively expressed at high levels in lymph
nodes [9]. Thus, mature DCs migrate from the sites of
antigen capture to T-cell regions of draining lymph nodes,
where they contact na¨ ıve or memory T cells and initiate a
speciﬁc immune response [3, 10] .I nt h i sm a n n e r ,D C sf o r m
the vital link between innate and adaptive immunity.
3.DCs Subsetsinthe Mouse
Murine DCs have been broadly divided into myeloid and
plasmacytoid populations. The myeloid DCs, currently
termed conventional DCs (cDCs), are further subdivided
into several subsets present in immune and nonimmune
tissues and organs specialized to perform diﬀerent functions
as described below. CD11c has been used as a typical marker
of murine cDCs although additional markers have been
used to distinguish these cells from other leukocytes such
as NK cells and B cells that can also express it. Indeed, all
cDC populations (except pre-DCs) are characterized by
expressing high levels of CD11c [11, 12]. In the steady state
cDCs present in lymphoid organs and tissues originated
from bone marrow precursors. As extensively reviewed by
Liu and Nussenzweig, 2010 [11], the mouse bone marrow
harbors a common DC precursor (CDP) characterized
by high expression of CD115 and Flt3, low expression of
CD117 (CD117lo), and is negative for lineage markers
CD3, NK1.1, B220, TER-119, and Gr-1 (Lin−)[ 13]. This
precursor is derived from a common monocyte and DC
precursor also present in the bone marrow [11, 13].
The CDP gives rise to a pre-DC circulating precursor
(CD11c+MHCII−SIRPαlo)thatrapidlyreachesthelymphoid
organs or tissues [11, 14]. As shown in Figure 1,t w om a j o r
DC subpopulations are present in mouse spleen in the steady
state, CD11chiMHCII+CD8α+CD205+SIRPα−CD11b−
and CD11chiMHCII+CD8α−33D1+SIRPα+CD11b+ cells
[11, 12]. As determined by elegant studies performed by
Dudziak et al. 2007, [15], the CD8α+ DC subpopulation
is specialized in cross-presentation, primarily presenting
peptides associated with MHC-I antigens, while the CD8α−
subpopulation is involved in presenting MHC-II-associated
peptides. It has been proposed that the CD8α+ splenic
population exclusively expresses the chemokine receptor
XCR1, thus being an excellent marker to investigate this
subpopulation in other species [16]. It has been recently
reported that this marker is also expressed by lymphatic
resident and migratory CD8α+ DCs [17], suggesting a
commonoriginforthesecells.Inaddition,ithasbeenshown
that the transcription factor Batf3 is selectively required for
the development of CD8α+ DC subset [18]. Although cDCs
were previously considered to be terminal mature cells,
growing evidence has determined that around 5% of spleen
DCs are actively diving at any given time [11, 12, 14, 19].
Similar CD8α+ and CD8α− DC populations to the ones
observed in mouse spleen are present in the lymph
nodes and thymus [11, 12]. In addition a CD11c+
MHCIIhilangerin+CD40hi DC migratory subpopulation
has been detected at the level of lymph node and tissues
[11]. cDC subpopulations have also been characterized as
CD11chiMHC+CD103+CD11b− or CD11chi MHC+CD103−
CD11b
hi in diﬀerent organs such as the liver, lung,
and kidney [11]. At the level of the intestine,
cDCs are populating both Peyer patches (CD11chiMHC+
CD103+CD11b
loCX3CR1− and CD11chiMHC+CD103−
CD11b
hiCX3CR1+) and lamina propria (CD11chiMHC+CD
103+ CD11b+CX3CR1−)[ 11]. Finally, the skin presents a
particular subtype of DCs, the LCs, which are considered
to be derived from a pre-LC precursor. These cells are
characterized by expression of CD103+CD11b
lolangerin+
or CD103−CD11b
hilangerin− (both in the dermis) and
CD11chiCD205lolangerin+EpCAMhi (epidermis) [20]. It has
been reported that epidermal Langerhans cells and langerin
dermal DCs constitute the vast majority of skin DCs, while
langerin dermal DCs represent 5% of all skin DCs [20].
Finally, conventional CD8α+ DC and CD103+ DCs
present in diﬀerent nonimmune tissues express similar Batf3
requirements, indicating that they might be closely develop-
mentally related [21].
The other main subset of DCs is comprised by plasma-
cytoid DCs (pDCs). In the mouse, these cells, also derived
from the CDP [14], are characterized by the expression of
B220, CD45RB, low or null levels of CD11c, and no CD11b
[22].CirculatingpDCshavethecapabilityofproducinglarge
amountsoftype1IFNin responsetoviralinfections[22,23]
and so are key mediators of the innate immune response
against viruses.
Diﬀerent protocols have been developed in order to
generate murine DC cultures. Usually, these cells are diﬀer-
entiated in vitro from bone marrow precursors using GM-
CSF alone or in combination with IL-4 [24–26]. The use ofJournal of Biomedicine and Biotechnology 3
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Figure 1: Conventional murine DCs in the steady state. Several DC subpopulations have been described in the mouse model colonizing
lymphoid organs and other tissues. Figure adapted from Motifolio Biomedical Toolkit Suite.
GM-CSF and/or IL-4 generates high amounts of dendritic
cells, capable of stimulating T cells in vitro and in vivo,w h i c h
have been extensively used in order to investigate DC: T cell
interactions, determine the eﬃcacy of DC-based vaccines,
and determine their role in pathological conditions such
infectious diseases or tumor models [27–34]. Alternatively,
in vitro generated DCs can be obtained from bone marrow
progenitors by treatment with fms-related tyrosine kinase
3 ligand (Flt3) and cytokines such as IL-6, stem cell factor,
IL3, or insulin-like growth factor [25, 26, 35]. The DC
populations generated upon culture of these precursors with
Flt3 have been considered to more closely resemble CD8α+
splenic DCs, particularly in their capability of producing IL-
12andorcross-presentantigens,althoughlackingexpression
of CD8α [36]. Finally, Flt3 can be also used for expansion of
murine DCs in vivo [35, 37].
4. MurineDC SubsetsduringInﬂammation
andDisease
It has been postulated that in the steady state murine DCs
only originate from DC precursors, while during inﬂam-
matory or pathological settings they might also arise from
monocytes and colonize lymphoid organs or nonimmune
tissues [38–42]. In addition, it has also been demonstrated
that, upon CD11c depletion, monocytes can contribute to
DC repopulation at the level of the intestine [43]. Recent
data has challenged this, suggesting that even in the steady
state some DC populations can arise from monocytes [44].
In particular, as reported by Jakubzick et al., 2008 [45], in the
absence of inﬂammation CD103+ and CD11b
hi pulmonary
DCs can, respectively, originate from two diﬀerent monocyte
populations characterized by the high or low expression of
Ly-6.
Nevertheless, particular DC populations are generated
under inﬂammatory conditions. For example, it has been
shown that a DC subset specialized in generating high
levels of TNFα and upregulating nitric oxide synthase II is
originated from monocytes during bacterial infections [40].
These TNF/iNOS-producing (Tip) DCs are recruited to the
spleen via CCR2 signaling and have been shown to mediate
the innate immune response against Listeria monocytogenes,
an intracellular bacterial pathogen [38].
The generation of particular DC populations has also
been observed in pathological conditions such as cancer.
For example, a DC subset with cytotoxic activity has
been described in the last years. This subset, named killer4 Journal of Biomedicine and Biotechnology
DC, is characterized by coexpression of B220 and NK1.1
receptors and is able to kill tumor cells, thus preventing
tumor growth when used in adoptive therapies [46–49].
These B220+CD11c+NK1.1+ DCs produce large amounts of
interferon γ (IFNγ) and are named IFN-producing killer
DCs (IKDCs). In vitro studies using fusokines (molecules
generated by fusing diﬀerent chemokines) have shown that
murine monocytes can be transformed into inducible killer
DCs with the capability of inducing apoptosis of tumor
cellswithoutlosingtheirantigenpresentingcapabilities[50].
In addition, treatment of bone marrow precursors with
MHC-I peptides in the context of a ligand epitope antigen
presentation system (LEAPS) is able to generate yet another
DC population characterized by expression of levels of IL-
12, thus being able to promote and steer immunity towards a
speciﬁc T helper-1 (Th1) response [51, 52].
Another subset of DCs described in tumor settings is
restricted to the spleen, express CD19, and suppresses T cells
responsesviaindoleamine2,3-dioxygenase(IDO)expression
[53–56]. The expression of IDO in these cells is triggered
upon CTLA4-mediated ligation of CD80 or CD86 molecules
[53].
Adding to the complexity of DC subsets, it has been
shown that some DC populations can change their phe-
notype under pathological settings. For example, pDCs
could acquire cDC characteristics under the inﬂuence of
viral infection [57]. This DC plasticity was evidenced by
pioneering work showing that CD8α− DCs can give rise to
other splenic DC subpopulations [58].
5.DCs inHumans
Characterization of DC populations in humans is challeng-
ing due to their low numbers in circulation (less than 1% of
blood mononuclear cells) and limited availability of healthy
tissuesasopposedtoanimalmodels.Asinthemouse,human
circulating DCs are broadly divided into pDCs and cDCs,
characterized by expression of MHC-II and CD11c−CD123+
(plasmacytoid) or CD11c+CD123− (conventional) antigens.
cDCs have been further divided into those characterized
by the expression of CD16, CD1c (BDCA-1), and CD141
(BDCA-3)[1,59].AsdescribedindetailbyMacDonaldetal.,
2002 [59], the circulating cDC population was composed by
40%–80% of CD16+ DCs, 20% to 50% of BDCA1+ DCs, and
2% to 3% of BDCA3+ DCs. Much eﬀort has been put into
determining the homology of these populations to murine
CD8α+ and CD8α− DC populations, although human cDCs
do not express this marker. Recent reports indicate that
BDCA3+ DCs might be the putative homologues of murine
CD8α+ DCs due to their expression of TLR-3, baft3 [60],
and XCR1 [16, 17, 61], their capability of producing IL-
12 upon stimulation [60], and their higher capability of
cross-presenting antigen when compared to CD16+ and
BDCA1+ DCs [60–62]. These DC populations can be also
detected in human spleens [60]. On the contrary, these cells
do not express TLR9 as their murine putative counterparts
[60]. In addition, array analysis clustered together human
BDCA3+ with mouse CD8α+ and human BDCA1+ with
murine CD8α− DCs [63].
Three diﬀerent DC subsets have been described in
human skin characterized by expression of CD1ahighCD14−
HLA-DR+, CD1adimCD14−HLA−DR+ DCs, and CD1a−
CD14+ HLA-DR+ DCs [64]. CD1ahighCD14−HLA-DR+
Langerhans cells reside in the epidermis, while the other
subsets reside in the dermis but contrary to what happens
in the mouse they do not express langerin [64].
Recently, 2 skin-derived and 2 resident human cDC
subsets were described in skin-draining lymph nodes char-
acterized by the expression of CD1a+CD11cint langerin+E-
cadherin+ (skin Langerhans cells); CD1a+CD11chi and vari-
able expression of langerin contrary to what was described
above (dermal Langerhans cells); CD14−BDCA3/CD141hi
CD103− and CD14+ BDCA3loCD103+ [65].
Finally, in order to generate high amount of DCs for
vaccination purposes, these cells have been prepared ex vivo
from monocytes or CD34+ precursors [66–68].
6.DCs andTCellResponses: The FourSignals
DCs play a multitude of roles in the development of an
antigen-speciﬁc immune response. Through the expression
of both MHC class I and MHC class II molecules, DCs are
able to interact with and activate na¨ ıve CD8+ Tc y t o t o x i c
and na¨ ıve CD4+ T helper lymphocytes, respectively [7, 10,
69]. For a na¨ ıve T lymphocyte to become an eﬀector cell
diﬀerent signals are required. The ﬁrst signal comes from
the direct interaction of the T cell receptor (TCR) of the
na¨ ıve T lymphocyte with the peptide bound to the MHC
molecule (Signal 1). The second signal required for na¨ ıve T
cell activation comes from DC: T cell interactions through
costimulatory molecules such as CD80 and CD86 on the
DC surface with CD28 on the T cell surface (Signal 2).
If costimulatory signaling fails to occur, the T lymphocyte
will not become activated and T cell anergy will ensue. The
third signal derived from DCs, which can lead to a speciﬁc
immune response, is T-cell diﬀerentiation through cytokine
signaling (Signal 3). There are multiple T helper subsets,
and the diﬀerentiation of na¨ ıve CD4+ T helper cells into
activated eﬀector T helper cells is directed by DC-derived
cytokines. Recently, it has been proposed that DCs give an
additional signal to T cells [70]. This signal 4 instructs T cells
to migrate to particular tissues by inducing the expression
of speciﬁc chemokine receptors and integrins in these cells
upon interaction with antigen-pulsed DCs [70].
Eﬀective activation of T cells will depend in the end
on the levels of expression and the interplay between
positive and negative costimulatory molecules in both DCs
and T cells. For example, antigen uptake in the absence
of inﬂammatory signals renders phenotypically immature
DCs, expressing low levels of MHC-II and costimulatory
molecules. Importantly, antigen presentation in the absence
of eﬀective positive costimulation can lead to T-cell anergy
and tolerance [71]. These DCs are considered “tolerogenic”
in comparison to “immunogenic” DCs capable of inducing
potent speciﬁc immune responses. Interestingly, DCs can
switch from immunogenic to tolerogenic depending on the
microenvironment conditions. For example, viral infectionsJournal of Biomedicine and Biotechnology 5
candiﬀerentiatepDCsintoT-helper-1-(Th1-)inducingDCs
[57]whileIL-3caninduceTh1-inducingDCstodiﬀerentiate
into Th-2-inducing ones [72].
7. Properties of the Tumor Microenvironment
Tumors are composed not only by tumor cells, but also by
other cellular types such as ﬁbroblasts, endothelial cells, and
inﬁltrating leukocytes that together with extracellular matrix
components constitute the microenvironment of the tumor.
Inrecent yearsthe relevanceof the tumormicroenvironment
as a key player in tumor development has been highlighted
and the role of its diﬀerent populations investigated. The
protective role of the immune system against tumors has
been widely described and tumor-inﬁltrating lymphocytes,
for example, have been associated with improved survival
of patients with melanoma, prostate, breast, colorectal,
and ovarian carcinomas, among others [73–76]. On the
contrary, tumor-associated leukocytes such as regulatory T
cells (Treg) or myeloid-derived suppressor cells (MDSCs)
canpromote tumorgrowthbyinhibiting antitumorimmune
responses [77, 78]. Indeed, we have previously demonstrated
the relevance of the tumor microenvironment in attracting
MDSCs by a complement-mediated process [79]. Further,
in a tumor setting a subset of spleen DCs with the
capability of suppressing T cells responses via indoleamine
2,3-dioxygenase (IDO) expression has been described [53].
In addition to suppressing the immune response, tumor-
associated leukocytes can also promote angiogenesis. Leuko-
cyte inﬁltration can precede the development of a neoplasm,
with being chronic inﬂammation being an important risk
factor for the development of cancer [80–82]. Indeed,
inﬂammatory conditions such as those caused by certain
types of infections can be involved in the pathogenesis of
many human malignancies. For example, gastric carcinomas
can arise in a H. pylori-induced gastritis environment [81]
or hepatitis B virus/hepatitis C virus can induce hepa-
tocellular carcinomas [82]. Also, chronic but noninfective
inﬂammatory conditions as in the case of smoking-related
bronchial cancer can induce carcinogenesis [83]. In the same
way, chronic pancreatitis is considered a risk factor for the
development of pancreatic cancer, and many of the growth
factors involved in tissue remodeling and regeneration in
chronic pancreatitis are present in pancreatic cancer [84].
In particular, inﬁltrating inﬂammatory cells secrete a diverse
repertoire of growth factors and proteases that enhance
tumor growth by stimulating angiogenesis. We and others
have described the capability of antigen presenting cells such
as DCs or macrophages, to collaborate with neoangiogenesis
in human cancers and in diﬀerent mouse tumor models
[5, 85–89].
8.Characteristicsof Tumor-AssociatedDCs
DCs are conspicuous members of the microenvironment
of several types of cancer [86, 90–93]. Tumor-associated
cytokinessuchasvascularendothelialgrowthfactor(VEGF),
interleukin-(IL-)10,andprostaglandinE-2(PGE2)canpro-
foundly aﬀect the nature of DCs [94]. Several reports indi-
cated that tumor-associated DCs (TA-DCs) are immunosup-
pressive, incapable of inducing speciﬁc immune responses,
or can induce regulatory T cell expansion. In particular, DCs
showing low levels of costimulatory molecules have been
detected in tumors expressing high levels of VEGF [95]. But
besides an immune “paralysis,” we and others have shown
that TA-DCs, or leukocyte expressing DC markers, are able
to produce angiogenic factors and can promote angiogenic
processes in the tumor microenvironment [79, 86, 93, 96].
Tumors require blood supply for expansive growth.
With increasing distance from vessels, hypoxic tumor cells
produce angiogenic factors that induce the formation of
neovessels [97–99]. Until recently, angiogenesis, or sprouting
of endothelial cells from existing vessels, was the only
accepted mechanism of tumor vascularization. Recent stud-
ies have suggested that vasculogenesis, or recruitment of
endothelial progenitors that diﬀerentiate into endothelial
cells, might contribute to the formation of tumor neovessels
[100]. Endothelial cell progenitors were ﬁrst identiﬁed by
expressionofthehematopoieticstemcellantigens,CD34and
ﬂk-1, and other hematopoietic stem cell antigens, such as
CD133 (AC133) [100]. Several populations of hematopoietic
cells assume an endothelial phenotype when cultured under
proangiogenic conditions. These include CD34+,S c a 1 +,
CD133+, and CD14+ cells. In particular, the capability a
CD34− monocytes to diﬀerentiate into endothelial-like cells
in vitro has been reported [101–103]. Further, diﬀerent
studies have demonstrated that monocytes or monocyte-
like cells can also function as endothelial cell progenitors
and incorporate into growing vasculature in experimental
models [104–106]. For example it has been recently shown
that monocytes, under the inﬂuence of proteins present in
the tumor microenvironment such as pleiotrophin or M-
CSF, transdiﬀerentiate into endothelial cells that incorporate
into tumor blood vessels [107]. In addition, interaction
of monocytes with extracellular matrix components such
as ﬁbronectin might also contribute to the monocyte-
endothelial cell transdiﬀerentiation process [108].
We and others have shown that DCs cultured in
the presence of tumor factors can undergo an endothe-
lization process characterized by the loss of CD14/CD45
and displayed endothelial markers such as CD31, CD34,
von Willebrand factor, vascular-endothelial-growth-factor-
receptor- (VEGFR-) 2, and VE-Cadherin [85, 109–112].
Furthermore, as we and others have shown, DCs can display
other characteristics of endothelial cells such as LDL uptake,
lectin binding, and formation of cord-like structures in 3D
gels [85, 109, 110] and are able to assemble into vascular
structures in vitro and in vivo, [85, 109, 110]. Although
this evidence suggests that DCs can transdiﬀerentiate into
endothelial cells, the capability of these cells of acting as
bonaﬁde endothelial cells is debatable. For example, we have
shown that tumor-associated DC precursors puriﬁed from
mouse or human ovarian carcinomas are able to participate
in the generation of neovessels in vivo [85, 88]. A follow-
up study by Huarte et al., 2008 [113], demonstrated that
these cells localize at the pericyte level in vivo in a mouse6 Journal of Biomedicine and Biotechnology
model of ovarian carcinoma, acting as a scaﬀold for the
generation of neovessels. Indeed, it has been shown that DCs
have the capability of intimately interacting with endothelial
cells and help to stabilize newly expanded vasculature at
the level of lymph nodes [114]. Thus, it is tempting to
speculate that in some tumor settings, this pericyte-like
function of DCs might help shape the characteristics of
tumor endothelium. In addition, DCs can also contribute to
angiogenesis by producing factors that promote growth of
bonaﬁde endothelial cells [115].
9.DendriticCellsasaSource
of Angiogenic Factors
WehaverecentlyshownthatmyeloidDCsareabletoproduce
a gamut of angiogenic molecules in vitro such as matrix
metalloproteases, VEGF, angiogenin, heparanase, and basis
ﬁbroblast growth factors [116]. We have also previously
shown that DC precursors participate in tumor progression
and angiogenesis in a mouse model of ovarian cancer [85].
For those studies, we used the ID8-Defb29/Vegf-A mouse
model of ovarian carcinoma. ID8 is a cell line derived from
spontaneous in vitro malignant transformation of C57BL/6
mouse ovarian surface epithelial cells that we engineered to
express mouse β-defensin 29 and VEGF-A. Our published
data support that this model mimics the pathophysiology of
human ovarian cancer which expresses both β-defensins and
levels of VEGF-A similar to our model. ID8-Defb29/Vegf-A
t u m o rc e l l sa r ea b l et og e n e r a t es o l i dt u m o ro ra s c i t e sw h e n
injected into syngeneic C57BL/6 mice subcutaneously or via
the intraperitoneal route respectively. In this tumor model,
immature DCs contribute to ovarian cancer progression by
acquiring a proangiogenic phenotype in response to VEGF
via VEGF-R2 [88, 115, 117]. Further, it has been shown
that depletion of TA-DCs in vivo reduces tumor growth
and decreases angiogenesis in this mouse model of ovarian
cancer [113, 118]. In the same way, data from the late
Dr. J. Folkman’s lab [119] highlighted the contribution of
DCs to angiogenesis in a murine model of endometriosis
and in the peritoneal Lewis lung carcinoma tumor model.
Similar to what we observed in our model, they showed that
these proangiogenic DCs have an immature phenotype, and
express VEGF-R2.
Taking into account all these data, it becomes clear that
tumors have the capability to attract and reprogram the
biology of DCs, inducing them to exert immunosuppressive
or angiogenic functions.
10.De ndriticC ellsandA ntitumo rThe rap y
Considerable eﬀort has been made in order to develop
strategies for using DCs to induce tumor-speciﬁc immunity,
including nearly 100 clinical trials designed to evaluate their
safety or eﬃcacy in humans [120]. The goal of DC-based
vaccination for antitumor therapy is to stimulate robust and
long lasting speciﬁc CD4 and CD8 T cell responses [121]. To
accomplishthis,severalstudieshavebeenperformedinorder
to generate DCs with the capability of inducing robust T cell
responses. For vaccination studies, DCs have been generated
from bone marrow precursors in the mouse and mostly from
m o n o c y t e si nh u m a n sa sd e s c r i b e da b o v e .D i ﬀerent steps in
the antigen presentation process have been evaluated such as
antigenloading,DCmaturation,anddeliveryrouteanddose
scheme.
Assayed methods of loading DCs with tumor-associated
antigens in the mouse model included pulsing the cells
with peptides derived from tumor antigens [122], whole
tumorlysates[123],apoptoticornecroticcells[124]aloneor
conjugated with toll-like receptor ligands [125], or antigens
coated with antibodies to target them to DCs via Fcγ recep-
tors [126]. We have showed that inducing the expression
of danger signals in tumor cells by means of replication-
deﬁcient or replication-restricted virus appears to be an eﬃ-
cient method to pulse DCs for vaccination purposes [124].
In addition, other strategies include encapsulating peptides
in biodegradable polymers that are phagocytized by DCs
[127],preparingDCsfusedwithtumorcells[128],orpulsing
DCs with RNA encoding tumor antigens [129]. In recent
years, the use of lentiviruses to induce stable transduction of
DCs has also been successfully evaluated [130–132]. These
vectors have the advantage of infecting nondividing cells,
thus being excellent tools to express diﬀerent molecules
in DCs. Moreover, hematopoietic stem cells have been
transduced with lentiviruses and then diﬀerentiated into
antigen-expressing DCs [133].
Similar studies have been performed using human DCs.
Among other strategies, these cells have been pulsed in vitro
with apoptotic or necrotic cells [134, 135], with nucleic acids
encoding tumor antigens [136, 137], or fused with tumor
cells [138] or pulsing DCs. An alternate method for loading
DCs with tumor antigen involves the insertion of full-length
antigens by genetic modiﬁcation using viral systems. Vector-
transferred recombinant antigens synthesized in the cytosol
of the cells may enter the degradation process of intracellular
molecules, yielding peptides that can be directly presented
by MHC-I molecules. Several viral vectors have been used
to transduce human DCs [139] including recombinant
adenoviruses [140–142], poxviruses [143], and retroviruses
[139]. Lentiviruses have also been used to induce stable
transduction of human hematopoietic stem cells or DCs
[144, 145].
This information regarding DC pulsing have been trans-
lated to the human, where clinical trials have involved,
amongothers,DCspulsedwithpeptides[146],whole-tumor
lysates [147], with RNA encoding tumor antigens [27, 148,
149], or fused with tumor cells [150, 151].
In order to improve DC-based vaccines for human
therapy, diﬀerent methods to induce DC maturation and
optimization of antigen processing and presentation have
also been proposed [121, 152]. The most widely used mat-
uration protocol for human monocyte-derived DCs employs
the combination of IL-6, tumor-necrosis-factor- (TNF-) α,
IL-1β, and PGE-2. Although these ex vivo matured DCs have
the capability to migrate towards lymph nodes, PGE-2 has
been shown to induce the production of IL-10 and VEGF,
which can be harmful in a tumor setting. Moreover, these
maturationstimulihavebeenshowntogeneratematureDCsJournal of Biomedicine and Biotechnology 7
capable of expanding regulatory T cells in vitro and in vivo
[153, 154]. Alternative protocols using diﬀerent TLR ligands
have been extensively studied [155–157].
In recent years a diﬀerent maturation cocktail has been
tested on human DCs. This cocktail, named the αDC1
cocktail, is composed of a combination of cytokines and TLR
ligands (IL-1β/TNFα/IFNα/IFNγ/poly-I:C) [156, 158, 159].
The αDC1 cocktail has been suggested as a better option
for maturation since treated DCs show higher migratory
responses to SLC, a CCR7 ligand constitutively produced
by lymph nodes, and produce higher levels of IL-12p70 as
compared to DCs matured with TNF-α,I L - 1 β,a n dP G E - 2
[155].Butsomedataarguesthatthiscocktaildoesnotinduce
better T cell activation [160]. Other proposed maturation
strategies for human DC vaccines involve activating tumor
antigen-pulsedDCswithCD40ligandbeforeinjection[161].
As previously reviewed in detail [162, 163], clinical trials
with DC vaccines have used diﬀerent methods of antigen
pulsing, maturation status of the cells, route of adminis-
tration, and dose scheme. The use of so many diﬀerent
strategies makes it diﬃcult to interpret in detail the causes
for the success or failure of the vaccinations, and argues for a
consensus regarding DC preparation, maturation, and route
a n dd o s es c h e m ef o rD C - b a s e dv a c c i n a t i o n s .
11.The FirstFDA-Approved
Antitumor DC Vaccine andthe
Challenges for Improvement
Recently, the ﬁrst autologous cellular vaccine for antitumor
therapies (Sipuleucel-T) has been approved by the Federal
andDrugAdministration (FDA) forthetreatmentofasymp-
tomatic or minimally symptomatic metastatic castrate-
resistant (hormone refractory) prostate cancer. In order to
generate the vaccine, the patients are subjected to apheresis
and the cells are cultured for 36–44h in a media containing
a synthetic protein generated by the fusion of prostatic acid
phosphatase and GM-CSF [164]. Then, this preparation
containing at least 50 million CD54+ antigen-presenting
cells is infused back into the patient. In all, the process
may consist of three cycles of apheresis, pulsing stimulation,
and reinfusions [164]. Sipuleucel-T therapy has shown
mild to moderate, short-term, reversible adverse events in
patients with no evidence of a treatment-related increase
in autoimmune complications or secondary malignancies
[165]. The treatment generates an increase in patient sur-
vival. In particular, it has been reported in a clinical trial that
the median survival in treated prostate cancer patients was
4.1 months longer (25.8 months) than in the placebo group
(21.7 months) [166]. Taking into account the promising but
rather modest increase in the patients’ survival, it becomes
clear that eﬀorts must be done in order to improve the
eﬃcacy of DC-based vaccines. A recent clinical trial in
human ovarian carcinoma shows that DC vaccine therapy
induced an increase in the antitumor immune response in
treated patients [167]. Interestingly, an impaired immune
response against an unrelated vaccine antigen in the same
patientshighlightstheimmunosuppressivestatusinducedby
tumors [167]. Thus, in order to increase the eﬃcacy of these
vaccines it might be interesting to block at the same time the
deleterious inﬂuence of the tumor microenvironment. The
role of the tumor microenvironment is also relevant, taking
into account that most human DC vaccines are generated
from monocytes, which, as described above, have a high
plasticity and can change their phenotype in response to
tumor factors.
12. Reprogramming the Tumor
Microenvironmentto Enhance
DC VaccinationEfﬁcacy
Ingeneral,althoughseveralreportsindicatethatDCvaccines
are able to induce immune responses in cancer patients,
they have only rarely resulted in objective clinical responses
based on the response evaluation criteria in solid tumors
(RECISTs) and no indication or evidence has been obtained
that DC vaccines represent a method of stimulating protec-
tive immunity in cancer patients that is superior to other
vaccination strategies [121]. One of the main reasons why
DC vaccines have been suboptimal in clinical trials might
be the inhibitory eﬀect of the tumor microenvironment.
As described above, the tumor microenvironment is highly
immunosuppressive due the presence of soluble factors such
as VEGF or IL-10 and immunosuppressive cell populations
such as MDSCs and Treg. This can aﬀect the eﬃcacy of
DC vaccination at diﬀerent levels. First, there could be
a direct eﬀect of soluble factors on DC-based vaccines,
impairing their immune capabilities. Indeed, it has been
shown in a clinical trial that ex vivo matured DCs, loaded
withtumorantigen,couldbetrappedbythetumormicroen-
vironment, thus rendering the immunization completely
ineﬀective [168]. Although this argues for an intranodal
immunization with DC vaccines, factors produced by the
tumor microenvironment can aﬀect distal tissues [169].
For example, VEGF, which is produced by several tumors,
can modify the immunological proﬁle of lymph nodes,
and the generation of immune precursors at primary and
secondary lymphoid organs [95, 170]. Thus, not only TA-
DCs might be aﬀected by the tumor microenvironment.
In addition, tumor-induced Treg and MDSCs can directly
impair the antitumor properties of T eﬀector cells induced
by DC vaccines. Taking into account this, in the last
years diﬀerent strategies have been proposed in order to
improve the eﬃcacy of DC vaccines by reprogramming the
immunosuppressive status of the tumor microenvironment.
The most common strategy has involved the combina-
tion of DC vaccination with Treg depletion. To accomplish
this, Tregs have been depleted in vivo by antibody therapy
with anti-CD25, a molecule expressed at high levels by
Tregs. In the mouse, promising results were obtained in
diﬀerent tumor models, where it was reported that Treg
depletionenhancedtheeﬃcacyofthevaccination[171–173].
In clinical trials, it has been shown that depletion of Tregs8 Journal of Biomedicine and Biotechnology
before vaccination with DCs pulsed with carcinoembryonic
antigen (CEA), enhanced speciﬁc T-cell immunity against
CEA in patients having a metastatic cancer expressing CEA,
asdeﬁnedbyimmunohistochemicalanalysisorelevatedCEA
in peripheral blood [174]. In addition, depletion of Tregs
also enhanced antitumor immunity in patients harboring
metastatic renal cell carcinomas [175]. In both trials, Tregs
were depleted by using denileukin diftitox, a fusion between
the active domain of diphtheria toxin and IL-2 that binds
cells expressing high levels of CD25. Upon internalization,
this molecule leads to cell death due to blockade of protein
synthesis. On the other hand, Jacobs et al., 2010 [176],
demonstrated in a phase I/II study in metastatic melanoma
that depletion of Tregs with daclizumab, a humanized
antibody directed against CD25, did not enhance antitumor
immunity in treated patients. These data point out that the
eﬃcacy of this combinatorial therapy might depend on the
type of cancer and the strategies used to deplete the Treg
population prior to vaccination.
A novel proposed combinatorial strategy assayed in the
mousemodelinvolvedaddingtheuseofCTLA-4blockadeto
Treg depletion in the context of DC-based vaccination [177].
In this study, CTLA-4 blockade and depletion of Treg cells
improved the potency of DC vaccination in a mouse model
coloncarcinomaexpressingbothCEAandHLA-A2antigens.
Other proposed strategies involve elimination of tumor
cells by radiotherapy, chemotherapy, antibody therapy, or
viral oncolytic therapy in combination with DC vaccination
as determined in animal models of lymphoma and prostate
cancer, among others [178–181]. This aims to decrease the
deleterious eﬀect of tumor cell products while generating
an inﬂammatory milieu that can enhance the eﬃcacy of
the vaccination. TA-DCs are usually described as immature
cells with low expression of costimulatory molecule and,
incapable of inducing robust antitumor immune responses
[182–185]. In this way, elimination of cancer cells will not
only generate tumor antigen that can be acquired by resident
DCs, but also abrogate the immunosuppressive milieu
generated by molecules produced by the same cancer cells.
In this new milieu, DCs that have acquired tumor antigen
might be able to turn into mature DCs, thus being able to
induce eﬀective immune responses.
Interestingly, depletion of TA-DCs from the tumor
microenvironment of ovarian cancer has been shown to
boost antitumor immune responses in the mouse model
[113]. Thus, depletion of these cells prior to DC-based vac-
cination may induce eﬀective antitumor immune responses.
Finally, albeit generating a speciﬁc immune response, vacci-
nation eﬀorts may fail due to the incapability of T cells to
reach their targets. Indeed, it has been previously shown that
diﬀerential expression of endothelin receptor B in murine
tumor endothelial cells determines the capability of T cells
of inﬁltrating tumors [186]. Thus, future strategies designed
to reprogram the tumor microenvironment to enhance
the eﬃcacy of DC vaccination might include blocking
endothelin receptor in endothelial cells to facilitate cytotoxic
T cell inﬁltration into the tumors.
13.Reprogramming DCs InSitutoInduce
Better Antitumor Immunity
As described above, DCs are present in the microenviron-
ment of diﬀerent tumors, but they are usually cells with
impaired capability of inducing antitumor eﬀector T cells.
A tantalizing strategy would be to reprogram these cells
in vivo, transforming them into eﬀective antigen-presenting
cells. Diﬀerent strategies are being developed and have been
assayed in the mouse model in order to speciﬁcally target
DCs in situ. For example, targeted delivery of antigens to
DCs via speciﬁc molecules expressed on the surface of these
cells has been investigated. Targeting ovalbumin to CD205
and 33D1 molecules on the surface of DCs in vivo helped
identify the antigen presenting properties of CD8α+ and
CD8α− DC subpopulations of splenic DCs [15]. Building on
these studies, eﬀective immunization procedures have been
obtained by using antibody-tumor antigen fusion proteins
targeting DCs via CD205 [187] or CD11c [188]. In addition,
antibodies speciﬁc for DC molecules have been used to coat
liposomes or nanoparticles in order to deliver antigens and
inﬂammatorycompoundstoDCsinsituinthemousemodel
[189]o rt ot a r g e th u m a nD C s[ 190]. Other strategies involve
generating DC vaccines that express tumor antigens under
a speciﬁc DC promoter, such as CD11c variant [191], or
engineering antigen-carrying lentiviral vectors capable of
selectively binding to DCs [192].
In the context of a murine ovarian cancer model, pio-
neering research has been performed by the Conejo-Garcia
group [193] in order to reprogram DCs in situ. By using
a mouse model of ovarian cancer, this group was able to
demonstrate that in situ activation of TA-DCs can induce
apotentantitumorimmuneresponse,creatingadefactovac-
cine with these cells. In order to accomplish this, they repro-
grammed TA-DCs by administration of linear polyethylen-
imine nanoparticles encapsulating nonviral siRNA. These
particles were avidly engulfed by TA-DCs, activating them
through TLR5 and inducing a potent antitumor immune
response. This strategy has the advantage of using the TA-
DCs, which might already harbor tumor antigens [194].
If translatable to humans, this will avoid costly ex vivo
preparation and pulsing of the patient’s DCs. This in situ
reprogramming of TA-DCs will beneﬁt by combinatorial
therapies destined to abrogate the immunosuppressive prop-
erties of the tumor microenvironment, such as using Treg
depletion therapies.
14. Summary and Outlook for
FutureDevelopment
Herewith we described that DCs comprise a population of
leukocytes with the capability of inducing speciﬁc immune
responses. These cells have the ability to capture antigens
and select and activate T cells capable of recognizing and
orchestrating an attack against the microbes or cells that
harbor the same antigen. This property had made DCs ideal
candidates for cellular vaccine therapies. DCs are divided
into diﬀerent subsets extensively investigated in the mouseJournal of Biomedicine and Biotechnology 9
model. In recent years a similar complexity has started to
unravel in humans. This heterogeneity is subjacent to a
characteristic that seems to be a hallmark of these cells:
their plasticity. It has been shown that these cells can
modify their phenotype in response to microenvironmental
factors. This characteristic seems to be exploited by tumors
that not only repress the maturation of these cells, thus
abrogating speciﬁc antitumor immune responses, but also
transform them into promoters of angiogenesis. In the
mouse model, it has been shown that DC-based vaccines can
eﬀectively induce antitumor immune responses. In humans,
a cellular DC-based vaccine has been recently approved
by the FDA for treatment of prostate cancer. In order to
build on this promising scenario, combinatorial therapies
destined to abrogate the deleterious inﬂuence of the tumor
microenvironment are being investigated. This will render
more powerful DC vaccines with the capability of generating
a robust and long-lasting antitumor immune response.
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